Crestor vs Amlodipine: Head-to-Head Efficacy Compared

Why Comparing Crestor and Amlodipine Requires Context

Rosuvastatin and amlodipine sit in entirely different pharmacologic classes, target distinct cardiometabolic risk factors, and are prescribed for different primary indications. A true head-to-head efficacy comparison (Drug A vs. Drug B for the same endpoint) does not exist in the published trial literature because no investigator would randomize a hypertensive patient to a statin alone, or a dyslipidemic patient to a calcium channel blocker alone.

What Each Drug Actually Does

Rosuvastatin (brand name Crestor) inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. The result is a dose-dependent drop in LDL cholesterol ranging from roughly 45% at 10 mg daily to 55% at 40 mg daily, according to prescribing data reviewed by the FDA [3]. Rosuvastatin also lowers triglycerides by 10-35% and raises HDL by 3-15%.

Amlodipine blocks L-type voltage-gated calcium channels in vascular smooth muscle, causing arterial vasodilation. This lowers peripheral resistance and reduces systolic blood pressure by an average of 12-15 mmHg at standard doses of 5-10 mg daily [4]. Amlodipine has no clinically meaningful effect on LDL cholesterol or triglycerides.

When the Question Makes Clinical Sense

The comparison becomes relevant in a specific clinical scenario: a patient with overlapping dyslipidemia and hypertension who needs both risk factors managed. In that setting, the question is not "which drug is better" but "what does each drug contribute to total cardiovascular risk reduction." The 2019 ACC/AHA Guideline on Primary Prevention of Cardiovascular Disease recommends treating both elevated LDL and elevated blood pressure as independent risk-lowering targets [5].

Rosuvastatin Efficacy: The JUPITER Trial and Beyond

The largest and most cited outcomes trial for rosuvastatin is JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), published in the New England Journal of Medicine in 2008 [1]. This trial reshaped how clinicians think about statin therapy in patients without overt dyslipidemia.

JUPITER Trial Design and Results

JUPITER enrolled 17,802 apparently healthy men (age 50+) and women (age 60+) with LDL cholesterol <130 mg/dL but high-sensitivity C-reactive protein (hsCRP) of 2.0 mg/L or higher. Participants received rosuvastatin 20 mg daily or placebo. The trial was stopped early, at a median follow-up of 1.9 years, because of a clear benefit signal in the treatment arm.

Key findings from JUPITER:

• 44% relative reduction in the primary composite endpoint of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death (HR 0.56, 95% CI 0.46-0.69, P<0.00001)
• 54% reduction in myocardial infarction
• 48% reduction in stroke
• 50% reduction in LDL cholesterol (from a median of 108 mg/dL to 55 mg/dL)
• 37% reduction in hsCRP

Other Rosuvastatin Outcome Data

The METEOR trial (2007) demonstrated that rosuvastatin 40 mg slowed progression of carotid intima-media thickness in patients with subclinical atherosclerosis compared to placebo over two years [6]. The ASTEROID trial showed actual regression of coronary atherosclerosis, measured by intravascular ultrasound, after 24 months of rosuvastatin 40 mg daily [7]. That finding was notable: atherosclerotic plaque volume decreased by a mean of 6.8%.

Amlodipine Efficacy: ASCOT and the Long-Term Record

Amlodipine's cardiovascular outcome evidence comes primarily from ASCOT-BPLA and ALLHAT, two large randomized trials that tested it against older antihypertensive classes.

ASCOT-BPLA Results

The Anglo-Scandinavian Cardiac Outcomes Trial, Blood Pressure Lowering Arm (ASCOT-BPLA), randomized 19,257 hypertensive patients with at least three additional cardiovascular risk factors to either amlodipine-based therapy (adding perindopril as needed) or atenolol-based therapy (adding bendroflumethiazide as needed) [2].

At a median follow-up of 5.5 years, the amlodipine-based regimen produced:

• 11% fewer major cardiovascular events (the primary endpoint did not reach statistical significance: HR 0.90, 95% CI 0.79-1.02, P=0.1052)
• 23% fewer strokes (P=0.0003)
• 24% fewer total cardiovascular events and procedures (P<0.0001)
• 11% lower all-cause mortality (P=0.0247)

The trial was stopped early by the data safety monitoring board because of the accumulating mortality difference.

ALLHAT Confirmation

ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) enrolled 33,357 hypertensive patients aged 55 and older. Amlodipine was compared against chlorthalidone and lisinopril over a mean follow-up of 4.9 years. The ALLHAT results showed no significant difference in the primary outcome (fatal CHD or nonfatal MI) between amlodipine and chlorthalidone, establishing amlodipine as an effective first-line antihypertensive [8].

Long-Term Safety and Durability

A 2018 Cochrane review of calcium channel blockers for primary hypertension confirmed that amlodipine-class drugs reduce stroke risk by approximately 38% relative to placebo and reduce total cardiovascular events by roughly 18% [9]. The effect is durable: amlodipine's 30-to-50-hour half-life makes it forgiving of missed doses, and the 10-year ASCOT Legacy data demonstrated persistent cardiovascular benefit even after in-trial treatment ended [10].

Comparing the Evidence: Indirect Analysis

Since no direct randomized comparison exists, clinicians and researchers rely on network meta-analyses and population-level data to understand the relative contributions of LDL lowering and blood pressure lowering to total cardiovascular risk.

Absolute Risk Reduction Differences

In JUPITER, the absolute risk reduction for the primary composite endpoint was 1.2 percentage points over 1.9 years (NNT = 95 per year of treatment in a primary prevention population with normal LDL but elevated hsCRP) [1].

In ASCOT-BPLA, the absolute risk reduction for all cardiovascular events and procedures was approximately 1.9 percentage points over 5.5 years in a higher-risk hypertensive population [2].

These numbers are not directly comparable. The JUPITER population had lower baseline cardiovascular risk (no prior events, LDL <130 mg/dL), while the ASCOT population had established hypertension with multiple additional risk factors. A patient's individual risk profile determines which intervention yields the larger absolute benefit.

The ASCOT-LLA Overlap

ASCOT included a lipid-lowering arm (ASCOT-LLA) in which 10,305 hypertensive patients with total cholesterol of 6.5 mmol/L or below were randomized to atorvastatin 10 mg or placebo, while continuing their randomized blood-pressure treatment. The ASCOT-LLA results showed a 36% relative reduction in coronary events with atorvastatin added on top of the blood-pressure regimen [11]. This is among the strongest evidence that combining a statin and an antihypertensive produces additive cardiovascular benefit.

A pre-specified analysis from ASCOT-LLA showed that patients randomized to both amlodipine-based BP therapy and atorvastatin had the lowest event rates of any subgroup, suggesting combination between the two drug classes [11].

What Pooled Data Show

The Cholesterol Treatment Trialists' (CTT) Collaboration meta-analysis of 26 statin trials (N=170,000) found that each 1 mmol/L (38.7 mg/dL) reduction in LDL cholesterol reduces major vascular events by approximately 22% over five years [12]. Separately, a meta-analysis by the Blood Pressure Lowering Treatment Trialists' Collaboration found that each 10 mmHg reduction in systolic blood pressure reduces major cardiovascular events by about 20%, stroke by 27%, and heart failure by 28% [13].

These proportional reductions are broadly similar in magnitude, reinforcing the clinical consensus: both LDL lowering and blood pressure lowering matter, and neither substitutes for the other.

When Clinicians Prescribe Both Together

Most cardiometabolic patients with both dyslipidemia and hypertension receive a statin and an antihypertensive concurrently. This is standard practice, not a special decision.

Fixed-Dose Combinations

Rosuvastatin-amlodipine fixed-dose combinations are approved in several countries outside the United States (for example, the combination is marketed in South Korea). A 2015 randomized controlled trial of 290 Korean patients with both hypertension and dyslipidemia found that the fixed-dose combination of rosuvastatin 20 mg plus amlodipine 5 mg reduced LDL cholesterol by 50.3% and systolic blood pressure by 8.5 mmHg at eight weeks, with no unexpected safety signals [14].

Drug Interaction Profile

Rosuvastatin and amlodipine have no clinically significant pharmacokinetic interaction. According to the rosuvastatin prescribing information, amlodipine does not affect rosuvastatin plasma concentrations [3]. Neither drug requires dose adjustment when prescribed with the other. The American College of Cardiology's 2019 guidelines recommend treating LDL and blood pressure as parallel targets in patients at elevated atherosclerotic cardiovascular disease (ASCVD) risk [5].

Side Effect Profiles Differ Substantially

Though this article focuses on efficacy, side effect profiles affect real-world effectiveness. A drug that works in trials but gets discontinued due to adverse effects loses its efficacy advantage.

Rosuvastatin Side Effects

The most common adverse effects of rosuvastatin are myalgia (reported by 2-11% of patients in trials), headache, and gastrointestinal symptoms. Serious but rare risks include rhabdomyolysis (estimated at 0.01-0.04% per year across all statins) and new-onset diabetes. In JUPITER, rosuvastatin increased physician-reported diabetes by 27% (HR 1.27, 95% CI 1.01-1.60), translating to roughly 1 extra case of diabetes per 167 patients treated over 1.9 years [1].

Amlodipine Side Effects

Peripheral edema is the hallmark adverse effect of amlodipine, occurring in 1.8% of patients at 5 mg and up to 10.8% at 10 mg per the FDA label [4]. Other reported effects include flushing, dizziness, and fatigue. Amlodipine does not carry metabolic risks like new-onset diabetes. Persistence rates for amlodipine are generally higher than for many other antihypertensive classes: a UK database study found 12-month persistence of 56% for amlodipine versus 50% for ACE inhibitors and 43% for thiazides [15].

Choosing Based on the Patient's Risk Profile

The decision between rosuvastatin and amlodipine is almost never "one or the other." It is driven by which cardiometabolic risk factors the patient actually has.

Rosuvastatin Is the Right Drug When

The primary problem is elevated LDL cholesterol, elevated non-HDL cholesterol, or elevated ASCVD risk that would benefit from lipid-lowering therapy. ACC/AHA guidelines identify four statin-benefit groups: clinical ASCVD, LDL 190 mg/dL or above, diabetes ages 40-75, and primary prevention with 10-year ASCVD risk of 7.5% or higher [5]. Rosuvastatin's potency makes it a preferred choice when large LDL reductions are needed. Dr. Paul Ridker, principal investigator of JUPITER, stated: "Rosuvastatin in JUPITER reduced events in a population previously not considered for statin therapy, expanding the indication beyond traditional lipid thresholds" [1].

Amlodipine Is the Right Drug When

The primary problem is hypertension, particularly systolic hypertension. Amlodipine is a first-line option per the 2017 ACC/AHA Hypertension Guideline, which recommends thiazides, ACE inhibitors, ARBs, or calcium channel blockers as initial therapy [16]. Amlodipine has specific advantages in older adults (long half-life, predictable effect), in Black patients (calcium channel blockers have shown particular efficacy in this population per ALLHAT), and in patients with concurrent angina.

Professor Peter Sever, lead investigator of ASCOT, noted: "The ASCOT findings showed not just blood-pressure reduction, but a broader cardiovascular protection with the amlodipine-based regimen that extended well beyond the trial period" [10].

Both Drugs Together When

The patient has coexisting hypertension and dyslipidemia, which describes a large proportion of adults over 50. The 2019 ACC/AHA primary prevention guideline explicitly recommends addressing both risk factors simultaneously, using 10-year ASCVD risk calculators to guide treatment intensity [5]. In ASCOT-LLA, the combination of a statin with an amlodipine-based blood pressure regimen produced additive cardiovascular benefit [11].

Practical Prescribing Differences

Rosuvastatin is dosed once daily, typically 5-40 mg, without regard to timing (morning or evening dosing produces equivalent LDL reductions due to its long half-life of 19 hours) [3]. Dose adjustments are needed in patients with severe renal impairment (eGFR <30 mL/min: maximum 10 mg).

Amlodipine is also dosed once daily, 2.5-10 mg, with no food requirement. Its half-life of 30-50 hours makes it the longest-acting dihydropyridine calcium channel blocker available. No dose adjustment is needed for renal impairment. Hepatic impairment warrants starting at 2.5 mg [4].

Both drugs are available as generics. Average retail prices for a 30-day supply range from $4-15 for generic rosuvastatin and $3-10 for generic amlodipine at most US pharmacies.